Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations - PubMed (original) (raw)
. 2005 Dec 1;106(12):3740-6.
doi: 10.1182/blood-2005-05-2164. Epub 2005 Jul 28.
Affiliations
- PMID: 16051734
- DOI: 10.1182/blood-2005-05-2164
Free article
Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations
Konstanze Döhner et al. Blood. 2005.
Free article
Abstract
To assess the prognostic relevance of mutations in the NPM1 gene encoding a nucleocytoplasmic shuttle protein in younger adults with acute myeloid leukemia (AML) and normal cytogenetics, sequencing of NPM1 exon 12 was performed in diagnostic samples from 300 patients entered into 2 consecutive multicenter trials of the AML Study Group (AMLSG). Treatment included intensive double-induction therapy and consolidation therapy with high cumulative doses of high-dose cytarabine. NPM1 mutations were identified in 48% of the patients including 12 novel sequence variants, all leading to a frameshift in the C-terminus of the nucleophosmin 1 (NPM1) protein. Mutant NPM1 was associated with specific clinical, phenotypical, and genetic features. Statistical analysis revealed a significant interaction of NPM1 and FLT3 internal tandem duplications (ITDs). NPM1 mutations predicted for better response to induction therapy and for favorable overall survival (OS) only in the absence of FLT3 ITD. Multivariable analysis for OS revealed combined NPM1-mutated/FLT3 ITD-negative status, CEBPA mutation status, availability of a human leukocyte antigen (HLA)-compatible donor, secondary AML, and lactate dehydrogenase (LDH) as prognostic factors. In conclusion, NPM1 mutations in the absence of FLT3 ITD define a distinct molecular and prognostic subclass of young-adult AML patients with normal cytogenetics.
Similar articles
- Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance.
Verhaak RG, Goudswaard CS, van Putten W, Bijl MA, Sanders MA, Hugens W, Uitterlinden AG, Erpelinck CA, Delwel R, Löwenberg B, Valk PJ. Verhaak RG, et al. Blood. 2005 Dec 1;106(12):3747-54. doi: 10.1182/blood-2005-05-2168. Epub 2005 Aug 18. Blood. 2005. PMID: 16109776 - Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report.
Ostronoff F, Othus M, Lazenby M, Estey E, Appelbaum FR, Evans A, Godwin J, Gilkes A, Kopecky KJ, Burnett A, List AF, Fang M, Oehler VG, Petersdorf SH, Pogosova-Agadjanyan EL, Radich JP, Willman CL, Meshinchi S, Stirewalt DL. Ostronoff F, et al. J Clin Oncol. 2015 Apr 1;33(10):1157-64. doi: 10.1200/JCO.2014.58.0571. Epub 2015 Feb 23. J Clin Oncol. 2015. PMID: 25713434 Free PMC article. - Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
Shamaa S, Laimon N, Aladle DA, Azmy E, Elghannam DM, Salem DA, Taalab MM. Shamaa S, et al. Hematology. 2014 Jan;19(1):22-30. doi: 10.1179/1607845413Y.0000000085. Epub 2013 Nov 25. Hematology. 2014. PMID: 23540998 - Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis.
Port M, Böttcher M, Thol F, Ganser A, Schlenk R, Wasem J, Neumann A, Pouryamout L. Port M, et al. Ann Hematol. 2014 Aug;93(8):1279-86. doi: 10.1007/s00277-014-2072-6. Epub 2014 May 7. Ann Hematol. 2014. PMID: 24801015 Review. - Incidence of FLT3 and nucleophosmin gene mutations in childhood acute myeloid leukemia: Serbian experience and the review of the literature.
Krstovski N, Tosic N, Janic D, Dokmanovic L, Kuzmanovic M, Spasovski V, Pavlovic S. Krstovski N, et al. Med Oncol. 2010 Sep;27(3):640-5. doi: 10.1007/s12032-009-9261-5. Epub 2009 Jun 26. Med Oncol. 2010. PMID: 19557552 Review.
Cited by
- A knock-in Npm1 mutation in mice results in myeloproliferation and implies a perturbation in hematopoietic microenvironment.
Chou SH, Ko BS, Chiou JS, Hsu YC, Tsai MH, Chiu YC, Yu IS, Lin SW, Hou HA, Kuo YY, Lin HM, Wu MF, Chou WC, Tien HF. Chou SH, et al. PLoS One. 2012;7(11):e49769. doi: 10.1371/journal.pone.0049769. Epub 2012 Nov 30. PLoS One. 2012. PMID: 23226219 Free PMC article. - Molecular prognostic factors in cytogenetically normal acute myeloid leukemia.
Walker A, Marcucci G. Walker A, et al. Expert Rev Hematol. 2012 Oct;5(5):547-58. doi: 10.1586/ehm.12.45. Expert Rev Hematol. 2012. PMID: 23146058 Free PMC article. Review. - FOXM1 contributes to treatment failure in acute myeloid leukemia.
Khan I, Halasi M, Patel A, Schultz R, Kalakota N, Chen YH, Aardsma N, Liu L, Crispino JD, Mahmud N, Frankfurt O, Gartel AL. Khan I, et al. JCI Insight. 2018 Aug 9;3(15):e121583. doi: 10.1172/jci.insight.121583. eCollection 2018 Aug 9. JCI Insight. 2018. PMID: 30089730 Free PMC article. - TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.
Metzeler KH, Maharry K, Radmacher MD, Mrózek K, Margeson D, Becker H, Curfman J, Holland KB, Schwind S, Whitman SP, Wu YZ, Blum W, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD. Metzeler KH, et al. J Clin Oncol. 2011 Apr 1;29(10):1373-81. doi: 10.1200/JCO.2010.32.7742. Epub 2011 Feb 22. J Clin Oncol. 2011. PMID: 21343549 Free PMC article. Clinical Trial. - Shift of N-MYC Oncogene Expression in AML Patients Carrying the FLT3-ITD Mutation.
Bogdanov K, Kudryavtseva E, Fomicheva Y, Churkina I, Lomaia E, Girshova L, Osipov Y, Zaritskey A. Bogdanov K, et al. Pathophysiology. 2023 Aug 1;30(3):296-313. doi: 10.3390/pathophysiology30030024. Pathophysiology. 2023. PMID: 37606386 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous